Literature DB >> 24748552

CXCR4 is highly expressed at the tumor front but not in the center of prostate cancers.

Nicolas Barry Delongchamps1, Frédéric Beuvon, Jacques R R Mathieu, Stéphanie Delmas, Isabelle Metzger, Hervé Prats, Florence Cabon.   

Abstract

OBJECTIVE: To evaluate the expression of CXCR4, its ligand SDF-1, β-catenin and E-cadherin throughout the local tumor microenvironment of prostate cancer. PATIENTS AND METHODS: A total of 64 prostate cancer specimens, 24 frozen and 40 paraffin-embedded sections, were obtained from patients treated with radical prostatectomy for clinically localized cancer. Real-time RT-PCR was used for mRNA quantification of CXCR4 and SDF-1 in the tumor center (T), tumor front (F) and distant peritumoral tissue (D). Immunohistochemical analysis was used to investigate the expression patterns of CXCR4, E-cadherin and β-catenin. Clinical records of these patients were studied for follow-up data, and the prognostic value of these molecules' expression was statistically assessed.
RESULTS: CXCR4 mRNA and protein were significantly increased at the tumor front as compared to distant tissue or tumor center. In comparison, SDF-1 mRNA level gradually increased from the tumor center to the distant peritumoral tissue. High CXCR4 at the tumor front was associated with high Gleason score. Low SDF-1 at the tumor front was associated with locally advanced cancer and disease recurrence. Moreover, high CXCR4 staining at the tumor front and increased cytosolic E-cadherin expression in the same location was associated with locally advanced disease.
CONCLUSIONS: CXCR4 seems overexpressed at the tumor front of prostate tumors, where it potentially promotes cell migration toward the SDF-1 centrifugal attracting gradient, as well as epithelial-mesenchymal transition. High CXCR4 and low SDF-1 levels at tumor front were both associated with adverse histological features.

Entities:  

Mesh:

Substances:

Year:  2014        PMID: 24748552     DOI: 10.1007/s00345-014-1299-0

Source DB:  PubMed          Journal:  World J Urol        ISSN: 0724-4983            Impact factor:   4.226


  27 in total

1.  NF-kappaB promotes breast cancer cell migration and metastasis by inducing the expression of the chemokine receptor CXCR4.

Authors:  Gregory Helbig; Kent W Christopherson; Poornima Bhat-Nakshatri; Suresh Kumar; Hiromitsu Kishimoto; Kathy D Miller; Hal E Broxmeyer; Harikrishna Nakshatri
Journal:  J Biol Chem       Date:  2003-04-09       Impact factor: 5.157

2.  The prognostic significance of proliferation-associated nucleolar protein p120 expression in prostate adenocarcinoma: a comparison with cyclins A and B1, Ki-67, proliferating cell nuclear antigen, and p34cdc2.

Authors:  B V Kallakury; C E Sheehan; S J Rhee; H A Fisher; R P Kaufman; M D Rifkin; J S Ross
Journal:  Cancer       Date:  1999-04-01       Impact factor: 6.860

3.  Evaluation of nuclear factor κB and chemokine receptor CXCR4 co-expression in patients with prostate cancer in the Radiation Therapy Oncology Group (RTOG) 8610.

Authors:  Meena Okera; Kyoungwha Bae; Eric Bernstein; Liang Cheng; Colleen Lawton; Harvey Wolkov; Alan Pollack; Adam Dicker; Howard Sandler; Christopher J Sweeney
Journal:  BJU Int       Date:  2010-12-13       Impact factor: 5.588

Review 4.  Regulation of angiogenesis by hypoxia-inducible factor 1.

Authors:  Kiichi Hirota; Gregg L Semenza
Journal:  Crit Rev Oncol Hematol       Date:  2006-05-22       Impact factor: 6.312

5.  Stromal cell-derived factor-1alpha and CXCR4 expression in hemangioblastoma and clear cell-renal cell carcinoma: von Hippel-Lindau loss-of-function induces expression of a ligand and its receptor.

Authors:  David Zagzag; Balaji Krishnamachary; Herman Yee; Hiroaki Okuyama; Luis Chiriboga; M Aktar Ali; Jonathan Melamed; Gregg L Semenza
Journal:  Cancer Res       Date:  2005-07-15       Impact factor: 12.701

6.  Skeletal localization and neutralization of the SDF-1(CXCL12)/CXCR4 axis blocks prostate cancer metastasis and growth in osseous sites in vivo.

Authors:  Yan-Xi Sun; Abraham Schneider; Younghun Jung; Jianhua Wang; Jinlu Dai; Jingcheng Wang; Kevin Cook; Nadir I Osman; Amy J Koh-Paige; Hyusuk Shim; Kenneth J Pienta; Evan T Keller; Laurie K McCauley; Russell S Taichman
Journal:  J Bone Miner Res       Date:  2004-11-16       Impact factor: 6.741

7.  CXCR4 nuclear localization follows binding of its ligand SDF-1 and occurs in metastatic but not primary renal cell carcinoma.

Authors:  Linhui Wang; Zhixiang Wang; Bo Yang; Qing Yang; Liang Wang; Yinghao Sun
Journal:  Oncol Rep       Date:  2009-12       Impact factor: 3.906

8.  Expression of CXCR4 and CXCL12 (SDF-1) in human prostate cancers (PCa) in vivo.

Authors:  Yan-Xi Sun; Jingcheng Wang; Charles E Shelburne; Dennis E Lopatin; Arul M Chinnaiyan; Mark A Rubin; Kenneth J Pienta; Russell S Taichman
Journal:  J Cell Biochem       Date:  2003-06-01       Impact factor: 4.429

9.  Transcriptional regulation of CXCR4 in prostate cancer: significance of TMPRSS2-ERG fusions.

Authors:  Rajareddy Singareddy; Louie Semaan; M Katie Conley-Lacomb; Jason St John; Katelyn Powell; Matthew Iyer; Daryn Smith; Lance K Heilbrun; Dongping Shi; Wael Sakr; Michael L Cher; Sreenivasa R Chinni
Journal:  Mol Cancer Res       Date:  2013-08-05       Impact factor: 5.852

10.  Cysteine (C)-x-C receptor 4 undergoes transportin 1-dependent nuclear localization and remains functional at the nucleus of metastatic prostate cancer cells.

Authors:  Ayesha S Don-Salu-Hewage; Siu Yuen Chan; Kathleen M McAndrews; Mahandranauth A Chetram; Michelle R Dawson; Danaya A Bethea; Cimona V Hinton
Journal:  PLoS One       Date:  2013-02-28       Impact factor: 3.240

View more
  7 in total

1.  Augmented migration of mesenchymal stem cells correlates with the subsidiary CXCR4 variant.

Authors:  Asieh Heirani-Tabasi; Hojjat Naderi-Meshkin; Maryam M Matin; Mahdi Mirahmadi; Mina Shahriyari; Naghmeh Ahmadiankia; Nasser Sanjar Moussavi; Hamid Reza Bidkhori; Mahmood Raeesolmohaddeseen; Ahmad Reza Bahrami
Journal:  Cell Adh Migr       Date:  2018-02-27       Impact factor: 3.405

2.  Tumor talk: understanding the conversation between the tumor and its microenvironment.

Authors:  Chery A Whipple
Journal:  Cancer Cell Microenviron       Date:  2015-04-26

Review 3.  The association of CXCR4 expression with clinicopathological significance and potential drug target in prostate cancer: a meta-analysis and literature review.

Authors:  Qi Chen; Tie Zhong
Journal:  Drug Des Devel Ther       Date:  2015-09-07       Impact factor: 4.162

4.  High RhoA expression at the tumor front in clinically localized prostate cancer and association with poor tumor differentiation.

Authors:  Weihua Chen; Nicolas Barry Delongchamps; Kaili Mao; Frédéric Beuvon; Michaël Peyromaure; Zhongmin Liu; Anh Tuan Dinh-Xuan
Journal:  Oncol Lett       Date:  2015-12-31       Impact factor: 2.967

5.  Transcriptome analysis reveals upregulation of immune response pathways at the invasive tumour front of metastatic seminoma germ cell tumours.

Authors:  Tim Nestler; Priya Dalvi; Friederike Haidl; Maike Wittersheim; Melanie von Brandenstein; Pia Paffenholz; Svenja Wagener-Ryczek; David Pfister; Ulrike Koitzsch; Martin Hellmich; Reinhard Buettner; Margarete Odenthal; Axel Heidenreich
Journal:  Br J Cancer       Date:  2022-01-12       Impact factor: 9.075

6.  CXCL12 promoter methylation and PD-L1 expression as prognostic biomarkers in prostate cancer patients.

Authors:  Diane Goltz; Emily Eva Holmes; Heidrun Gevensleben; Verena Sailer; Jörn Dietrich; Maria Jung; Magda Röhler; Sebastian Meller; Jörg Ellinger; Glen Kristiansen; Dimo Dietrich
Journal:  Oncotarget       Date:  2016-08-16

7.  Evaluation of Somatostatin and CXCR4 Receptor Expression in a Large Set of Prostate Cancer Samples Using Tissue Microarrays and Well-Characterized Monoclonal Antibodies.

Authors:  Christoph Werner; Olaf Dirsch; Uta Dahmen; Marc-Oliver Grimm; Stefan Schulz; Amelie Lupp
Journal:  Transl Oncol       Date:  2020-05-24       Impact factor: 4.243

  7 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.